Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
复制标题
DOI：
10.1002/ijc.24241
复制
发表时间：
2009-06-01
影响因子：
6.4
通讯作者：
Mucci, Lorelei A.
中科院分区：
文献类型：
--
作者：
Stark, Jennifer Rider;Li, Haojie;Kraft, Peter;Kurth, Tobias;Giovannucci, Edward L.;Stampfer, Meir J.;Ma, Jing;Mucci, Lorelei A.
白细胞介素-6（IL-6）和C反应蛋白（CRP）在前列腺癌患者中升高，但这些炎症介质的诊断前水平对前列腺癌预后的作用尚不清楚。我们进行了一项大型前瞻性病例对照研究，以评估诊断前IL-6和CRP水平与前列腺癌发病率和死亡率之间的关系。我们还研究了IL-6（−174 G/C）多态性与IL-6和CRP循环水平以及癌症风险和死亡率的关系。我们使用非条件Logistic回归分析，调整匹配因素，分析前列腺癌的风险。对于前列腺癌死亡率的分析，我们对病例进行了生存分析。由于炎症标志物和BMI之间的密切联系，我们评估了BMI和血浆水平对前列腺癌预后的相互作用。IL-6基因型对IL-6和CRP血浆水平无显著影响。基因型与前列腺癌风险或生存率无关。尽管IL-6和CRP与前列腺癌发病率总体上均无相关性，但我们观察到IL-6和BMI在前列腺癌发病率上具有统计学显著的交互作用（p <0.01）。增加IL-6水平与健康体重男性的风险呈正相关，但与超重男性的风险呈负相关。此外，在健康体重前列腺癌病例中，诊断前IL-6与前列腺癌进展/死亡的时间相关（ptrend=0.02）。比较最高与最低IL-6水平，校正的风险比为1.73（95% CI：0.86，3.51）。我们的研究表明，IL-6可能参与前列腺癌的发生或进展。
Interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated in prostate cancer patients, but the role of pre-diagnostic levels of these inflammatory mediators on prostate cancer outcomes is unclear. We undertook a large, prospective case-control study to evaluate the relation between pre-diagnostic levels of IL-6 and CRP and prostate cancer incidence and mortality. We also investigated the role of the IL-6 (−174 G/C) polymorphism in relation to circulating levels of IL-6 and CRP, as well as cancer risk and mortality. We used unconditional logistic regression that adjusted for matching factors to analyze prostate cancer risk. For analyses of prostate cancer mortality, we conducted survival analyses in cases. Because of the strong link between inflammatory markers and BMI, we assessed interactions between BMI and plasma levels on prostate cancer outcomes. Neither IL-6 nor CRP plasma levels varied significantly by IL-6 genotype. Genotype was not associated with prostate cancer risk or survival. Though neither IL-6 nor CRP was associated with prostate cancer incidence overall, we observed a statistically significant interaction between IL-6 and BMI on prostate cancer incidence (pinteraction<0.01). Increasing IL-6 levels were positively associated with risk in healthy weight men, but inversely associated with risk in overweight men. Further, pre-diagnostic IL-6 was associated with time to prostate cancer progression/death among healthy weight prostate cancer cases (ptrend=0.02). Adjusted hazard ratios were 1.73 (95% CI: 0.86, 3.51) comparing the highest to lowest IL-6 level. Our study suggests that IL-6 may potentially be involved in the development or progression of prostate cancer.
登录
查看更多内容
影响因子：
8.8
作者：
McArdle, PA;McMillan, DC;Underwood, MA
通讯作者：
Underwood, MA
影响因子：
11.2
作者：
Michaud, DS;Daugherty, SE;Hayes, RB
通讯作者：
Hayes, RB
DOI：
10.1111/j.1432-1033.1988.tb14384.x
发表时间：
1988-11-01
期刊：
EUROPEAN JOURNAL OF BIOCHEMISTRY
影响因子：
--
作者：
CASTELL, JV;GEIGER, T;HEINRICH, PC
通讯作者：
HEINRICH, PC
影响因子：
158.5
作者：
HENNEKENS, CH
通讯作者：
HENNEKENS, CH
影响因子：
15.9
作者：
Fishman, D;Faulds, G;Woo, P
通讯作者：
Woo, P